Last reviewed · How we verify
RAL or EGV based ARV regimens with ABC
Inhibits HIV-1 integrase
Inhibits HIV-1 integrase Used for HIV-1 infection.
At a glance
| Generic name | RAL or EGV based ARV regimens with ABC |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV-1 integrase inhibitor |
| Target | HIV-1 integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor (INSTI). It blocks the integration of viral DNA into the host cell genome, preventing viral replication.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAL or EGV based ARV regimens with ABC CI brief — competitive landscape report
- RAL or EGV based ARV regimens with ABC updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI